Kura Oncology Q4 Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy KURA?
Source: seekingalpha
- Disappointing Earnings: Kura Oncology reported a Q4 GAAP EPS of -$0.92, missing expectations by $0.18, indicating challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company’s Q4 revenue of $17.34 million represents a 67.8% year-over-year decrease, falling short of the expected $18.11 million, reflecting a notable weakness in product sales and market demand that could lead to future cash flow pressures.
- Cash Reserves Situation: As of December 31, 2025, Kura's cash and short-term investments totaled $667.2 million, down from $727.4 million in 2024, highlighting urgency in financial management that may impact the execution of its operational plans.
- Future Funding Strategy: Kura believes its current cash and investments will fund operations into Q4 2027, and combined with the anticipated $180 million from the collaboration with Kyowa Kirin, these resources are expected to support the ziftomenib AML program, despite facing short-term financial pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KURA
Wall Street analysts forecast KURA stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.680
Low
16.00
Averages
29.71
High
40.00
Current: 9.680
Low
16.00
Averages
29.71
High
40.00
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Kura Oncology Reports Promising Kidney Cancer Trial Results
- Trial Results: Kura Oncology presented initial results from the FIT-001 trial at the International Kidney Cancer Symposium, revealing an objective response rate of 44% and a disease control rate of 94%, indicating significant potential for the treatment of advanced kidney cancer.
- Tumor Shrinkage: Among the 16 patients, 75% experienced tumor shrinkage, particularly those with previously limited responses to Cabozantinib, suggesting the treatment may be effective for hard-to-treat cases.
- Safety Profile: The study demonstrated a manageable safety profile, with Darlifarnib administered alongside Cabozantinib at daily doses of 3 mg, 5 mg, or 8 mg in a 7 days on, 7 days off cycle, ensuring good tolerability across different dose levels.
- Market Reaction: Following the clinical data release, KURA shares surged over 13% in pre-market trading, potentially reaching their highest levels since January 2026, reflecting investor optimism about the company's future prospects.
See More
Kura Oncology Reports Positive Data for Kidney Cancer Drug
- Clinical Trial Results: Kura Oncology's FIT-001 trial shows that darlifarnib combined with cabozantinib resulted in tumor shrinkage in 75% of patients, indicating a potential shift in treatment paradigms for renal cell carcinoma.
- Patient Response Rates: Among 16 patients previously treated with cabozantinib, darlifarnib demonstrated a 44% objective response rate and a 94% disease control rate, highlighting its efficacy in difficult-to-treat cases.
- Treatment Duration: Treatment durations ranged from 8 to 86 weeks, showcasing darlifarnib's adaptability and potential long-term efficacy across different patients, offering new hope for those affected.
- Market Outlook: Kura's Chief Medical Officer emphasized that these data highlight darlifarnib's potential to overcome cabozantinib resistance, potentially laying the groundwork for further advancements in the kidney cancer market.
See More
Kura Oncology Reveals New Data on Darlifarnib and Cabozantinib Combination Therapy Potential
- Clinical Data Highlights: In the FIT-001 clinical trial, the combination of darlifarnib and cabozantinib demonstrated a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib, indicating significant antitumor activity in refractory patients.
- Tumor Shrinkage Effects: Among treated patients, 75% experienced tumor shrinkage, with reductions ranging from 32% to 47%, showcasing the efficacy of this treatment regimen particularly in heavily pretreated patients who had stable disease on prior cabozantinib therapy.
- Good Tolerability: All renal cell carcinoma patients across various doses of cabozantinib exhibited a manageable safety and tolerability profile, with treatment durations reaching up to 56 weeks, further validating the clinical applicability of this combination.
- Future Outlook: Kura Oncology plans to further evaluate the darlifarnib and cabozantinib combination therapy in subsequent studies, aiming to provide more effective treatment options for renal cell carcinoma patients, especially in settings where existing therapies are limited.
See More
Kura Oncology Presents Darlifarnib Clinical Data at IKCS Europe 2026
- Clinical Trial Update: Kura Oncology will present updated data from the FIT-001 clinical trial on April 17, 2026, at the International Kidney Cancer Symposium, evaluating the efficacy of darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, indicating potential improvements in patient treatment outcomes.
- Efficacy and Safety: The combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile at the 2025 ESMO Congress, suggesting its potential as a new treatment option for patients with advanced renal cell carcinoma.
- Virtual Investor Call: Kura will host a virtual investor call on April 17, 2026, featuring management and clinical investigators discussing the latest developments in the darlifarnib program, which may enhance investor confidence in the company's future growth.
- Drug Mechanism: Darlifarnib, a next-generation farnesyl transferase inhibitor, is designed to inhibit the farnesylation of RHEB, thereby enhancing the activity of multiple targeted therapies, including VEGFR-targeted therapies, potentially offering more effective treatment options for renal cancer patients.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Kura Oncology granted 153,750 nonstatutory stock options to six new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.34 per share, matching the closing price on the grant date, which serves to incentivize employees to grow alongside the company.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring that new employees maintain their service relationship during the vesting period to enhance long-term commitment.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, continuously enhancing the company's competitiveness in the biopharmaceutical industry.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Kura Oncology Reports Promising Kidney Cancer Trial Results
- Trial Results: Kura Oncology presented initial results from the FIT-001 trial at the International Kidney Cancer Symposium, revealing an objective response rate of 44% and a disease control rate of 94%, indicating significant potential for the treatment of advanced kidney cancer.
- Tumor Shrinkage: Among the 16 patients, 75% experienced tumor shrinkage, particularly those with previously limited responses to Cabozantinib, suggesting the treatment may be effective for hard-to-treat cases.
- Safety Profile: The study demonstrated a manageable safety profile, with Darlifarnib administered alongside Cabozantinib at daily doses of 3 mg, 5 mg, or 8 mg in a 7 days on, 7 days off cycle, ensuring good tolerability across different dose levels.
- Market Reaction: Following the clinical data release, KURA shares surged over 13% in pre-market trading, potentially reaching their highest levels since January 2026, reflecting investor optimism about the company's future prospects.
See More
Kura Oncology Reports Positive Data for Kidney Cancer Drug
- Clinical Trial Results: Kura Oncology's FIT-001 trial shows that darlifarnib combined with cabozantinib resulted in tumor shrinkage in 75% of patients, indicating a potential shift in treatment paradigms for renal cell carcinoma.
- Patient Response Rates: Among 16 patients previously treated with cabozantinib, darlifarnib demonstrated a 44% objective response rate and a 94% disease control rate, highlighting its efficacy in difficult-to-treat cases.
- Treatment Duration: Treatment durations ranged from 8 to 86 weeks, showcasing darlifarnib's adaptability and potential long-term efficacy across different patients, offering new hope for those affected.
- Market Outlook: Kura's Chief Medical Officer emphasized that these data highlight darlifarnib's potential to overcome cabozantinib resistance, potentially laying the groundwork for further advancements in the kidney cancer market.
See More
Kura Oncology Reveals New Data on Darlifarnib and Cabozantinib Combination Therapy Potential
- Clinical Data Highlights: In the FIT-001 clinical trial, the combination of darlifarnib and cabozantinib demonstrated a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib, indicating significant antitumor activity in refractory patients.
- Tumor Shrinkage Effects: Among treated patients, 75% experienced tumor shrinkage, with reductions ranging from 32% to 47%, showcasing the efficacy of this treatment regimen particularly in heavily pretreated patients who had stable disease on prior cabozantinib therapy.
- Good Tolerability: All renal cell carcinoma patients across various doses of cabozantinib exhibited a manageable safety and tolerability profile, with treatment durations reaching up to 56 weeks, further validating the clinical applicability of this combination.
- Future Outlook: Kura Oncology plans to further evaluate the darlifarnib and cabozantinib combination therapy in subsequent studies, aiming to provide more effective treatment options for renal cell carcinoma patients, especially in settings where existing therapies are limited.
See More
Kura Oncology Presents Darlifarnib Clinical Data at IKCS Europe 2026
- Clinical Trial Update: Kura Oncology will present updated data from the FIT-001 clinical trial on April 17, 2026, at the International Kidney Cancer Symposium, evaluating the efficacy of darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, indicating potential improvements in patient treatment outcomes.
- Efficacy and Safety: The combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile at the 2025 ESMO Congress, suggesting its potential as a new treatment option for patients with advanced renal cell carcinoma.
- Virtual Investor Call: Kura will host a virtual investor call on April 17, 2026, featuring management and clinical investigators discussing the latest developments in the darlifarnib program, which may enhance investor confidence in the company's future growth.
- Drug Mechanism: Darlifarnib, a next-generation farnesyl transferase inhibitor, is designed to inhibit the farnesylation of RHEB, thereby enhancing the activity of multiple targeted therapies, including VEGFR-targeted therapies, potentially offering more effective treatment options for renal cancer patients.
See More
Kura Oncology Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Kura Oncology granted 153,750 nonstatutory stock options to six new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: Each stock option has an exercise price of $8.34 per share, matching the closing price on the grant date, which serves to incentivize employees to grow alongside the company.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring that new employees maintain their service relationship during the vesting period to enhance long-term commitment.
- Strategic Positioning: Kura Oncology focuses on precision medicine, committed to developing innovative drugs targeting cancer, particularly in hematologic malignancies and solid tumors, continuously enhancing the company's competitiveness in the biopharmaceutical industry.
See More
